It is not about Size & Beds but governance in Private Hospitals in India. Indian Hospitals need a major makeover

It is not about Size & Beds but governance in Private Hospitals in India. Indian Hospitals need a major makeover

Cost Reduction, improving quality of care and access for patients are challenges as Global Hospitals, Apollo Hospitals Group, Fortis Healthcare, Care Hospitals & Manipal Hospitals compete to win coveted India’s Most Best Managed Healthcare Chain 2013

Image

Saturday, November 23, 2013, Mumbai, Maharashtra : India’s medical tourism boom—a $1 billion business that is growing by 30% a year is being regarded by the analysts & experts as one of the fastest & growing sector in healthcare services worldwide as india’s top private hospitals have expanded their healthcare services remarkably both in size & geographies. Health services in India have to be affordable because their patients are poor and typically pay 60 percent of their medical costs out of pocket & without healthcare insurance in place, Indian Hospital majors are facing the heat of price reduction & globalizing healthcare standards. As Healthcare Industry in india mainly the hospital chains are beginning to change their approach, Pharmaleaders ( www.pharmaleaders.tv ), Asia’s most analytical news media in healthcare has nominated top five hospitals in india such as Global Hospitals, Apollo Hospitals Group, Fortis Healthcare, Care Hospitals & Manipal Hospitals for public voting to determine who has the edge in corporate HR & Managed Healthcare in the category of “India’s Most Best Managed Healthcare Chain 2013” at the historic sixth edition of Pharmaceutical Leadership Summit & Business Leadership Awards 2013 ( www.pharmaleaders2013.com ). This widely acclaimed meet is held annually to recognize the best amongst the best based on their yearly performances.

The experience of a few innovative Indian hospitals may point the way forward. India’s health care system as a whole has many problems, mainly on the issue of governance & affordable medical care. The quality of doctors, equipment and infrastructure has been the hallmark of healthcare excellence in Indian hospital industry & The Indian experience shows that costs can be dramatically reduced and access can be expanded even as quality is improved.

The study point out that  private hospitals deliver medical outcomes comparable to that of good U.S. hospitals, as measured by medical complication rates or post-treatment survival rates. Furthermore, they’re profitable. Even if Indian hospitals paid U.S.-level salaries for all health-care staff, which are as much as 20 times higher, their prices would be one-fifth of U.S. levels. By contrast, hospitals in the United States are uncoordinated, duplicating specialized care without enough volume in most of them to make procedures affordable. Even when hospitals consolidate, the motive is often to gain pricing power over insurance companies rather than to lower costs.The second innovation is shifting responsibility for routine tasks to lower-skilled workers. This leaves doctors free to focus on complicated procedures. Several hospitals have created a tier of paramedic workers with two years of training after high school to perform routine medical jobs. As a result, surgeons, for instance, can perform two to three times as many surgeries as their U.S. counterparts. Compare that with the United States, where hospitals reduce costs by laying off support staff, which shifts mundane tasks such as billing to doctors, who are overqualified for such duties.Finally, the Indian hospitals save money through old-fashioned frugality. They shepherd resources by building hospitals at a fraction of the cost spent in the United States, replacing imported devices with local equivalents costing a fraction of the price or, for example, sterilizing and reusing clamps for open-heart surgery that are routinely discarded after one use in the United States. In contrast to the American fee-for-service model, they often pay their doctors a fixed salary. One hospital sends a daily message to all doctors with the previous day’s financial results, encouraging them to consider the cost-effectiveness of their medical choices. In contrast, U.S. hospitals often resemble luxury hotels, with much wasted space and underutilized equipment. Their doctors, and sometimes even their chief financial officers, are unaware of how much procedures cost.How realistic is it that U.S. hospitals will adopt the Indian model? U.S. hospitals are constrained by regulations and norms unlike those in India. Nevertheless, some progressive U.S. hospitals are adopting some of the practices of our Indian exemplars, and more should follow their example.

India might be the last place on earth where you’d expect to find health care innovation. Government programs have finally brought some infectious diseases under control, but the nation’s ability to meet the basic medical needs of its citizens remains abysmal. Despite robust economic growth over the past two decades, the infant mortality rate is three times higher than China’s and seven times greater than that of the U.S. Of the 2 million Indians in need of heart surgery, fewer than 5% get it. The majority of the country’s estimated 63 million diabetics and 2.5 million cancer sufferers haven’t been diagnosed, let alone treated. Seventy percent of India’s 12 million blind people could be cured by a simple surgery—if it were available to them.

Although India boasts 750,000 doctors and 1.1 million nurses, practitioner density is about one-fourth what it is in the U.S. and less than half that of China. Hospital beds are in short supply, and most medical facilities are dated, cramped, and often unhygienic. In a country where the nominal per capita income is only $1,500 a year, patients typically have to pay 60% of health care expenses from their own pockets. Still, Indians believe that good medical treatment is something everyone should have access to regardless of their ability to pay.

Necessity spawns innovation. Despite the pressing demand and constrained supply, a few relatively new Indian hospitals have devised ways of providing world-class health care affordably—and to scale. These hospitals target well-off patients, which forces them to provide care that meets global quality standards. But their purpose is to serve everyone, including patients with very low incomes, which puts pressure on the organizations to lower costs dramatically. Such a business model scales because the low costs of these hospitals attract large volumes of patients and allow the overall enterprise to be profitable. As a result, the hospitals are able to sustain their operations not through the usual government subsidies, charitable donations, or insurance reimbursements but through their revenues.

The Indian hospitals we studied treat medical conditions that range from problems of the eye, heart, and kidney to maternity care, orthopedics, and cancer. Their charges for most procedures are as much as 95% lower than those at U.S. hospitals. How are some Indian hospitals able to provide such high-quality health care at ultralow prices? The obvious answer—the differential in the cost of labor—does play a role: Cardiothoracic surgeons, nephrologists, ophthalmologists, and oncologists in India earn anywhere from 20% to 74% of what their American counterparts do.

These Five Hospitals put together would constitute more than 30,000 Beds & will excel in healthcare services & the competition is intense as the prices of services of the consultants are increasing posing a challenge to meet the budget of the patients.

As india votes to select the coveted India’s Most Best Managed Healthcare Chain 2013 by public voting, it will be a challenge to crown the one of the five to be declared on 27th December 2013 at Mumbai at Pharmaleaders Incredible Pharmaleaders 2013 Meet where more than 250 healthcare leaders will assemble to discuss healthcare reforms.  

Advertisements

It is not about Size & Beds but governance in Private Hospitals in India. Indian Hospitals need a major makeover

It is not about Size & Beds but governance in Private Hospitals in India. Indian Hospitals need a major makeover

Cost Reduction, improving quality of care and access for patients are challenges as Global Hospitals, Apollo Hospitals Group, Fortis Healthcare, Care Hospitals & Manipal Hospitals compete to win coveted India’s Most Best Managed Healthcare Chain 2013

Image

Saturday, November 23, 2013, Mumbai, Maharashtra : India’s medical tourism boom—a $1 billion business that is growing by 30% a year is being regarded by the analysts & experts as one of the fastest & growing sector in healthcare services worldwide as india’s top private hospitals have expanded their healthcare services remarkably both in size & geographies. Health services in India have to be affordable because their patients are poor and typically pay 60 percent of their medical costs out of pocket & without healthcare insurance in place, Indian Hospital majors are facing the heat of price reduction & globalizing healthcare standards. As Healthcare Industry in india mainly the hospital chains are beginning to change their approach, Pharmaleaders ( www.pharmaleaders.tv ), Asia’s most analytical news media in healthcare has nominated top five hospitals in india such as Global Hospitals, Apollo Hospitals Group, Fortis Healthcare, Care Hospitals & Manipal Hospitals for public voting to determine who has the edge in corporate HR & Managed Healthcare in the category of “India’s Most Best Managed Healthcare Chain 2013” at the historic sixth edition of Pharmaceutical Leadership Summit & Business Leadership Awards 2013 ( www.pharmaleaders2013.com ). This widely acclaimed meet is held annually to recognize the best amongst the best based on their yearly performances.

The experience of a few innovative Indian hospitals may point the way forward. India’s health care system as a whole has many problems, mainly on the issue of governance & affordable medical care. The quality of doctors, equipment and infrastructure has been the hallmark of healthcare excellence in Indian hospital industry & The Indian experience shows that costs can be dramatically reduced and access can be expanded even as quality is improved.

The study point out that  private hospitals deliver medical outcomes comparable to that of good U.S. hospitals, as measured by medical complication rates or post-treatment survival rates. Furthermore, they’re profitable. Even if Indian hospitals paid U.S.-level salaries for all health-care staff, which are as much as 20 times higher, their prices would be one-fifth of U.S. levels. By contrast, hospitals in the United States are uncoordinated, duplicating specialized care without enough volume in most of them to make procedures affordable. Even when hospitals consolidate, the motive is often to gain pricing power over insurance companies rather than to lower costs.The second innovation is shifting responsibility for routine tasks to lower-skilled workers. This leaves doctors free to focus on complicated procedures. Several hospitals have created a tier of paramedic workers with two years of training after high school to perform routine medical jobs. As a result, surgeons, for instance, can perform two to three times as many surgeries as their U.S. counterparts. Compare that with the United States, where hospitals reduce costs by laying off support staff, which shifts mundane tasks such as billing to doctors, who are overqualified for such duties.Finally, the Indian hospitals save money through old-fashioned frugality. They shepherd resources by building hospitals at a fraction of the cost spent in the United States, replacing imported devices with local equivalents costing a fraction of the price or, for example, sterilizing and reusing clamps for open-heart surgery that are routinely discarded after one use in the United States. In contrast to the American fee-for-service model, they often pay their doctors a fixed salary. One hospital sends a daily message to all doctors with the previous day’s financial results, encouraging them to consider the cost-effectiveness of their medical choices. In contrast, U.S. hospitals often resemble luxury hotels, with much wasted space and underutilized equipment. Their doctors, and sometimes even their chief financial officers, are unaware of how much procedures cost.How realistic is it that U.S. hospitals will adopt the Indian model? U.S. hospitals are constrained by regulations and norms unlike those in India. Nevertheless, some progressive U.S. hospitals are adopting some of the practices of our Indian exemplars, and more should follow their example.

India might be the last place on earth where you’d expect to find health care innovation. Government programs have finally brought some infectious diseases under control, but the nation’s ability to meet the basic medical needs of its citizens remains abysmal. Despite robust economic growth over the past two decades, the infant mortality rate is three times higher than China’s and seven times greater than that of the U.S. Of the 2 million Indians in need of heart surgery, fewer than 5% get it. The majority of the country’s estimated 63 million diabetics and 2.5 million cancer sufferers haven’t been diagnosed, let alone treated. Seventy percent of India’s 12 million blind people could be cured by a simple surgery—if it were available to them.

Although India boasts 750,000 doctors and 1.1 million nurses, practitioner density is about one-fourth what it is in the U.S. and less than half that of China. Hospital beds are in short supply, and most medical facilities are dated, cramped, and often unhygienic. In a country where the nominal per capita income is only $1,500 a year, patients typically have to pay 60% of health care expenses from their own pockets. Still, Indians believe that good medical treatment is something everyone should have access to regardless of their ability to pay.

Necessity spawns innovation. Despite the pressing demand and constrained supply, a few relatively new Indian hospitals have devised ways of providing world-class health care affordably—and to scale. These hospitals target well-off patients, which forces them to provide care that meets global quality standards. But their purpose is to serve everyone, including patients with very low incomes, which puts pressure on the organizations to lower costs dramatically. Such a business model scales because the low costs of these hospitals attract large volumes of patients and allow the overall enterprise to be profitable. As a result, the hospitals are able to sustain their operations not through the usual government subsidies, charitable donations, or insurance reimbursements but through their revenues.

The Indian hospitals we studied treat medical conditions that range from problems of the eye, heart, and kidney to maternity care, orthopedics, and cancer. Their charges for most procedures are as much as 95% lower than those at U.S. hospitals. How are some Indian hospitals able to provide such high-quality health care at ultralow prices? The obvious answer—the differential in the cost of labor—does play a role: Cardiothoracic surgeons, nephrologists, ophthalmologists, and oncologists in India earn anywhere from 20% to 74% of what their American counterparts do.

These Five Hospitals put together would constitute more than 30,000 Beds & will excel in healthcare services & the competition is intense as the prices of services of the consultants are increasing posing a challenge to meet the budget of the patients.

As india votes to select the coveted India’s Most Best Managed Healthcare Chain 2013 by public voting, it will be a challenge to crown the one of the five to be declared on 27th December 2013 at Mumbai at Pharmaleaders Incredible Pharmaleaders 2013 Meet where more than 250 healthcare leaders will assemble to discuss healthcare reforms.  

Infinite Computer’s Upinder Zutshi to receive prestigious Business Leader of the Year 2013 (Healthcare & IT)

Infinite Computer’s Upinder Zutshi to receive prestigious Business Leader of the Year 2013 (Healthcare & IT)

 

Healthcare IT Leader Upinder Zutshi selected by the Pharmaleaders Jury for bringing innovations in Healthcare Solutions &delivering greater value with new products and information tools at a lower cost

Image

Friday,22nd November 2013, Mumbai, Maharashtra, India : Healthcare industry worldwide is fast changing with the increase in the healthcare reforms, rising chronic diseases & healthcare companies increasingly passionate in bringing low cost healthcare solutions in various areas to improve the quality of healthcare services by using latest technologies. The 6th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2013 ( www.pharmaleaders2013.com ) organized by Network 7 Media Group’s leading media Pharmaleaders(www.pharmaleaders.tv ) is organizing asia’s most eagerly awaited healthcare summit Incredible Pharmaleaders 2013, Billion Dreams – Pushing India’s Growth Agenda on 27th December 2013 in Mumbai, India has been at the forefront of raising significant issues that is grappling the sector worldwide.

In an announcement to the media, Pharmaleaders declared Upinder Zutshi, the dynamic & visionary IT Leader Upinder Zutshi of Infinite Computer Solutions as the Business Leader of the Year 2013 ( Healthcare & IT) for the remarkable progress made in the healthcare IT domain spearheading Infinite’s global healthcare solutions & establishing dominant leadership acumen. Announcing the coveted title, Satya Brahma, Chairman of the Oeganising Committee of the 6th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leaders Awards 2013 said “Upinder Zutshi’s continued concentration in bringing affordable healthcare solutions to the wide array of healthcare services & the ability to compete in the fiercely competitive market coupled with the innovation in identifying the needs of the healthcare enterprises resulted in chosing the prestigious title in a non-voting individual category from the top it leaders of the country”. At a time when the global economic slowdown compelling the healthcare players to reduce their healthcare IT budget, Upinder has successfully innovated low cost IT Solutions in hospital and outpatient management, healthcare reform, regulatory compliance, care coordination & management, clinical analytics & business intelligence,icd-10 transition revenue cycle management, elf service & patient engagement, enterprise applications Outsourcing & European North American, Asia Pacific & Middle East Will form the biggest market for Infinite in 2015..”

Reaching out to Pharmaleaders selection & announcement, Upinder Zutshi, CEO & MD of Infinite Computers Solutions said “ It is indeed a big honour & at the same time brings a bigger responsibility on my shoulder to perform better in the healthcare domain. Our total revenue from the overall business in healthcare domain is 18 % & Infinite Computers is confident to double the numbers in coming years as more & more healthcare companies are coming forward to repose faith in our services said Upinder.

Elaborating more on the services, elated Upinder emphasized that Infinite helps health plan organizations focused on delivering greater value with new products and information tools at a lower cost. Our strengths lie in business process improvements, fully managed care implementations and the upgrade of legacy equipment, all while complying with new regulations. Infinite has the edge in Applications that enable Claims Processing, Legacy Systems Modernization,Health Analytics & Business Intelligence,ICD-10 Transition,Healthcare Reform Compliance,Managed Care Product Configuration and Implementation,Quality and Claims Auditing and Reporting. Our solution includes A comprehensive Electronic Medical Records (EMR) Solution for deployment across Clinics and Hospitals in the US,This EMR solution meets the unique needs of primary care, urgent care, occupational medicine, and various other specialties,Automates most of the processes and provides easy access to patient’s clinical information, thereby enhancing the practitioner’s ability to provide premium patient care,EMR system tracks the patient through the entire clinical/ hospital procedures and enables the end-user to generate a comprehensive clinical note, submit claims electronically and maintain patient’s health information and accounts,The system also integrates with the e-RX exchange to facilitate electronic prescriptions directly to the pharmacies& the solution is ONC-ATCB 2011 /2012 certified,EMR also provides interfaces for external laboratories, billing system and pharmacies.

 

It is pertinent here to note that The global healthcare IT market is estimated to reach $56.7 billion by 2017–up from $40.4 billion in 2012–due to the demand for clinical information technology, administrative solutions and services. The primary reasons for growth, according to the report, include the pressure to cut healthcare costs, demand to integrate healthcare systems,High rate of return on investment in healthcare systems, Financial support and incentives from the U.S. government, Medical tourism in the Asian region, Government initiatives, the rise in the aging population, Growing demand of CPOE adoption in order to reduce medication errors, A rise in incidences of chronic disorders.

The rising need to continuously monitor and care for health has increased the global expenditure on healthcare services and products. The trend is also gradually pushing people towards home healthcare products and services, due to their cost efficiency and reliability. This, in turn, is driving the growth of the global home healthcare products and services market. The technological and application developments that have taken place in the home healthcare segment have made them more reliable and globally acceptable. It has also made it feasible for hospitals and patients to get early discharge, and minimize the cost and infrastructure pressures. The growth in certain diseases or medical conditions such as high blood pressure, diabetes, asthma, and other cardiovascular and respiratory diseases, which require continuous monitoring and care, are further driving the home healthcare market growth. Though the global share of the home healthcare equipment market is considerably less, it is growing at a faster CAGR of 9.9% from 2012 to 2018 due to rising technological innovations, especially in the field of home therapeutic equipment. The home healthcare services market, despite its large share, is expected to grow at a CAGR of 7.4% from 2012 to 2018. The main deterrent, restricting the entry of organized players in this segment is dominance of a large number of small regional players, who are offering their services at low prices, and enjoy high customer loyalty. This has in turn, shifted the attention of big players towards the home healthcare equipment market.

Upinder Zutshi will receive the prestigious title of the Business Leader of the Year in Healthcare & IT on Friday, 27th December 2013 in Mumbai, india in a power-packed & glittering award ceremony where Pharmaleaders will felicitate top 40 leaders in different categories 

Infinite Computer’s Upinder Zutshi to receive prestigious Business Leader of the Year 2013 (Healthcare & IT)

Infinite Computer’s Upinder Zutshi to receive prestigious Business Leader of the Year 2013 (Healthcare & IT)

 

Healthcare IT Leader Upinder Zutshi selected by the Pharmaleaders Jury for bringing innovations in Healthcare Solutions &delivering greater value with new products and information tools at a lower cost

Image

Friday,22nd November 2013, Mumbai, Maharashtra, India : Healthcare industry worldwide is fast changing with the increase in the healthcare reforms, rising chronic diseases & healthcare companies increasingly passionate in bringing low cost healthcare solutions in various areas to improve the quality of healthcare services by using latest technologies. The 6th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2013 ( www.pharmaleaders2013.com ) organized by Network 7 Media Group’s leading media Pharmaleaders(www.pharmaleaders.tv ) is organizing asia’s most eagerly awaited healthcare summit Incredible Pharmaleaders 2013, Billion Dreams – Pushing India’s Growth Agenda on 27th December 2013 in Mumbai, India has been at the forefront of raising significant issues that is grappling the sector worldwide.

In an announcement to the media, Pharmaleaders declared Upinder Zutshi, the dynamic & visionary IT Leader Upinder Zutshi of Infinite Computer Solutions as the Business Leader of the Year 2013 ( Healthcare & IT) for the remarkable progress made in the healthcare IT domain spearheading Infinite’s global healthcare solutions & establishing dominant leadership acumen. Announcing the coveted title, Satya Brahma, Chairman of the Oeganising Committee of the 6th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leaders Awards 2013 said “Upinder Zutshi’s continued concentration in bringing affordable healthcare solutions to the wide array of healthcare services & the ability to compete in the fiercely competitive market coupled with the innovation in identifying the needs of the healthcare enterprises resulted in chosing the prestigious title in a non-voting individual category from the top it leaders of the country”. At a time when the global economic slowdown compelling the healthcare players to reduce their healthcare IT budget, Upinder has successfully innovated low cost IT Solutions in hospital and outpatient management, healthcare reform, regulatory compliance, care coordination & management, clinical analytics & business intelligence,icd-10 transition revenue cycle management, elf service & patient engagement, enterprise applications Outsourcing & European North American, Asia Pacific & Middle East Will form the biggest market for Infinite in 2015..”

Reaching out to Pharmaleaders selection & announcement, Upinder Zutshi, CEO & MD of Infinite Computers Solutions said “ It is indeed a big honour & at the same time brings a bigger responsibility on my shoulder to perform better in the healthcare domain. Our total revenue from the overall business in healthcare domain is 18 % & Infinite Computers is confident to double the numbers in coming years as more & more healthcare companies are coming forward to repose faith in our services said Upinder.

Elaborating more on the services, elated Upinder emphasized that Infinite helps health plan organizations focused on delivering greater value with new products and information tools at a lower cost. Our strengths lie in business process improvements, fully managed care implementations and the upgrade of legacy equipment, all while complying with new regulations. Infinite has the edge in Applications that enable Claims Processing, Legacy Systems Modernization,Health Analytics & Business Intelligence,ICD-10 Transition,Healthcare Reform Compliance,Managed Care Product Configuration and Implementation,Quality and Claims Auditing and Reporting. Our solution includes A comprehensive Electronic Medical Records (EMR) Solution for deployment across Clinics and Hospitals in the US,This EMR solution meets the unique needs of primary care, urgent care, occupational medicine, and various other specialties,Automates most of the processes and provides easy access to patient’s clinical information, thereby enhancing the practitioner’s ability to provide premium patient care,EMR system tracks the patient through the entire clinical/ hospital procedures and enables the end-user to generate a comprehensive clinical note, submit claims electronically and maintain patient’s health information and accounts,The system also integrates with the e-RX exchange to facilitate electronic prescriptions directly to the pharmacies& the solution is ONC-ATCB 2011 /2012 certified,EMR also provides interfaces for external laboratories, billing system and pharmacies.

 

It is pertinent here to note that The global healthcare IT market is estimated to reach $56.7 billion by 2017–up from $40.4 billion in 2012–due to the demand for clinical information technology, administrative solutions and services. The primary reasons for growth, according to the report, include the pressure to cut healthcare costs, demand to integrate healthcare systems,High rate of return on investment in healthcare systems, Financial support and incentives from the U.S. government, Medical tourism in the Asian region, Government initiatives, the rise in the aging population, Growing demand of CPOE adoption in order to reduce medication errors, A rise in incidences of chronic disorders.

The rising need to continuously monitor and care for health has increased the global expenditure on healthcare services and products. The trend is also gradually pushing people towards home healthcare products and services, due to their cost efficiency and reliability. This, in turn, is driving the growth of the global home healthcare products and services market. The technological and application developments that have taken place in the home healthcare segment have made them more reliable and globally acceptable. It has also made it feasible for hospitals and patients to get early discharge, and minimize the cost and infrastructure pressures. The growth in certain diseases or medical conditions such as high blood pressure, diabetes, asthma, and other cardiovascular and respiratory diseases, which require continuous monitoring and care, are further driving the home healthcare market growth. Though the global share of the home healthcare equipment market is considerably less, it is growing at a faster CAGR of 9.9% from 2012 to 2018 due to rising technological innovations, especially in the field of home therapeutic equipment. The home healthcare services market, despite its large share, is expected to grow at a CAGR of 7.4% from 2012 to 2018. The main deterrent, restricting the entry of organized players in this segment is dominance of a large number of small regional players, who are offering their services at low prices, and enjoy high customer loyalty. This has in turn, shifted the attention of big players towards the home healthcare equipment market.

Upinder Zutshi will receive the prestigious title of the Business Leader of the Year in Healthcare & IT on Friday, 27th December 2013 in Mumbai, india in a power-packed & glittering award ceremony where Pharmaleaders will felicitate top 40 leaders in different categories 

Zuventus Healthcare, Aristo Pharma, Indoco Remedies, Blucross Labs & Ajanta Pharma in the Race to Win Doctors Heart

Zuventus Healthcare, Aristo Pharma, Indoco Remedies, Blucross Labs & Ajanta Pharma in the Race to Win Doctors Heart

6th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2013 to decide the most respected company preferred by the Indian medical practitioners.

ImageImage

Wednesday, 20th November 2013, Mumbai, Maharashtra: As the momentum for the Pharmaleaders’s (www.pharmaleaders.tv ) 6th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2013 (www.pharmaleaders2013.com ) is going bigger & bigger, the coveted & prestigious category for the India’s Most Respected Company by the Medical Practitioners 2013 is being widely debated amongst the professionals of the healthcare industry in view of the value attached to the medical profession. Organised by Pharmaleaders, Asia’s most analytical news media in healthcare, the forum will debate Incredible Pharmaleaders 2013 – Billion Dreams by the stalwarts of the pharmaceutical Industry & the veterans from the medical practice. Rated by the industry analysts & trade pundits as the most credible platform for debating significant issues, the historic 6th edition by pharmaleaders is concentrating on the relationship between the pharma companies & the doctors. More than 100 top medical practitioners in india & abroad are expected to attend this leadership summit while 200 CEO’s of the Healthcare companies have blocked their calendar for the annual affair. In the limelight is the nomination category of India’s Most Respected Company by Medical Practitioners 2013 where India’s top five leading pharmaceutical companies such as 1.Zuventus Healthcare Ltd, Indoco Remedies Ltd,2.Aristo Pharmaceuticals Ltd,3.Ajanta Pharma Ltd,4.Blu-Cross Laboratories Ltd.

As per the figures available with Pharmaleaders, india has close to 7 million registered Indian medical doctors. There are 387 medical colleges in the country—181 in government and 206 in private sector. India produces 30,000 doctors, 18,000 specialists, 30,000 AYUSH graduates, 54,000 nurses, 15,000 ANMs and 36,000 pharmacists annually. Health ministry claims that there are about 6-6.5 lakh doctors available. But India would need about four lakh more by 2020 to maintain the required ratio of one doctor per 1,000 people. It is widely known that the major pharma players in the branded formulation market spend millions in building brands to win the hearts of the doctors to get the patronage & prescriptions, however, as per the latest research available to pharmaleaders & the survey conducted in major towns revealed that doctors have become increasingly conscious of the product endorsements. There is also an increasing competition amongst the pharma companies to satisfy the increasing demands of the doctors.

Against the background of the prevailing medical practice & market conditions, the image of pharma companies are of utmost importance says Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders, India is a challenging market where the promotion of the brands to the doctors & building the sustainable approach to the mindset of the doctors is a huge task & involves hard work & big bucks. All the five major players in the Nomination category such as 1.Zuventus Healthcare Ltd, Indoco Remedies Ltd,2.Aristo Pharmaceuticals Ltd,3.Ajanta Pharma Ltd,4.Blu-Cross Laboratories Ltd are enjoying the market dominance in their respective therapeutic segments & have employed innovative strategies to woo them, the final verdict lies with the doctors as nearly 35000 doctors will vote the coveted title, ‘India’s Most Respected Company by Medical Practitioners 2013”. While the first generation entrepreneur Prakash Guha is spearheading Zuventus Healthcare, veteran Suresh Kare is driving Indoco Remedies, Sharma Brothers are running the Aristo Brand & Isranis & Purushottam Agrawal are driving Blucross & Ajanta Pharma respectively.

The Indian pharmaceutical market (IPM) is currently valued at Rs 72,069 crore as against Rs 65,654 crore in 2012 & though Though the market value has seen an increase, the sector overall has experienced a slowdown with its growth going down to 9.8% from 16.6% in 2012. This slowdown can be attributed to the new drug pricing policy and the regulatory interventions over the last year, The industry is witnessing additional challenges like delays in clinical trial approvals, uncertainties over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing. The slowdown is also evident from the number of new product launches, which has gone down from approximately 1900 in year 2010 to 1700 in year 2012. The contribution of chronic therapies to the IPM has gone up from 27% in 2010 to 30% in 2013. Chronic therapies (cardio, gastro, CNS and anti-diabetic) have outperformed the market for the past four years and are growing at a rate of 14%, faster than the acute therapies (anti-infectives, respiratory, pain and gynaec) which grew at 9.6%. “The economic environment in India is tougher now than ever before. While pharma companies focus their attention on measures to combat the growth slowdown, they will need to work with the government and other stakeholders to discuss and resolve regulatory challenges. Resolving the impasse with clinical trials is critical both for patients and India’s ambition to innovate.”.According to the report, India is perceived as an attractive destination for clinical trials but has been marred with genuine concerns. Clinical trials are an inherent part of the drug development process and cannot be dispensed with. The continuing search for new therapies and cost-effective alternatives to existing therapies will be realised in practice only after comprehensive clinical trials.The clinical research industry in India needs to work closely with the government to create a regulatory mechanism that allows scientifically sound and ethically correct trials to be conducted so that the benefits of clinical trials can be brought to patients in India.The industry is also facing stricter regulations on manufacturing and quality practices in the domestic as well as he international markets. Indian companies will have to raise their compliance to US FDA regulations as they drive their major share of exports from the US market.The implementation of the National Pharmaceutical Pricing Policy 2012 by the Government of India has resulted in margins erosion from 20% and 10% to 16% and 8% for retailers and stockists, respectively. This decrease in the stockist margins led to a significant uncertainty among many stockists regarding the feasibility of staying in business due to lower profitability post the margin reduction.

The final result of the winner will be declared on the award presentation ceremony on Friday, 27th December 2013 in Mumbai, India.

Contacts :

6th Annual Pharmaceutical Leadership Summit 
Unit No. 53, 2nd Floor,
Aditya Indistrial Estate,
Devrukhkarwadi, Chincholi Bunder,
Malad (W), Mumbai – 400 064
Phone: + 91 22 4248 1240 / 4248 1234 / 4248 1235
Mr Anish Khan : ++ 91 9819499475
Ms Amrapali : ++ 91 9594030372 
Email : registrations@pharmaleaders2013.com
Email : pharmasummit2013@webevents.in 
Web : http://www.pharmaleaders2013.com

Zuventus Healthcare, Aristo Pharma, Indoco Remedies, Blucross Labs & Ajanta Pharma in the Race to Win Doctors Heart

Zuventus Healthcare, Aristo Pharma, Indoco Remedies, Blucross Labs & Ajanta Pharma in the Race to Win Doctors Heart

6th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2013 to decide the most respected company preferred by the Indian medical practitioners.

ImageImage

Wednesday, 20th November 2013, Mumbai, Maharashtra: As the momentum for the Pharmaleaders’s (www.pharmaleaders.tv ) 6th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2013 (www.pharmaleaders2013.com ) is going bigger & bigger, the coveted & prestigious category for the India’s Most Respected Company by the Medical Practitioners 2013 is being widely debated amongst the professionals of the healthcare industry in view of the value attached to the medical profession. Organised by Pharmaleaders, Asia’s most analytical news media in healthcare, the forum will debate Incredible Pharmaleaders 2013 – Billion Dreams by the stalwarts of the pharmaceutical Industry & the veterans from the medical practice. Rated by the industry analysts & trade pundits as the most credible platform for debating significant issues, the historic 6th edition by pharmaleaders is concentrating on the relationship between the pharma companies & the doctors. More than 100 top medical practitioners in india & abroad are expected to attend this leadership summit while 200 CEO’s of the Healthcare companies have blocked their calendar for the annual affair. In the limelight is the nomination category of India’s Most Respected Company by Medical Practitioners 2013 where India’s top five leading pharmaceutical companies such as 1.Zuventus Healthcare Ltd, Indoco Remedies Ltd,2.Aristo Pharmaceuticals Ltd,3.Ajanta Pharma Ltd,4.Blu-Cross Laboratories Ltd.

As per the figures available with Pharmaleaders, india has close to 7 million registered Indian medical doctors. There are 387 medical colleges in the country—181 in government and 206 in private sector. India produces 30,000 doctors, 18,000 specialists, 30,000 AYUSH graduates, 54,000 nurses, 15,000 ANMs and 36,000 pharmacists annually. Health ministry claims that there are about 6-6.5 lakh doctors available. But India would need about four lakh more by 2020 to maintain the required ratio of one doctor per 1,000 people. It is widely known that the major pharma players in the branded formulation market spend millions in building brands to win the hearts of the doctors to get the patronage & prescriptions, however, as per the latest research available to pharmaleaders & the survey conducted in major towns revealed that doctors have become increasingly conscious of the product endorsements. There is also an increasing competition amongst the pharma companies to satisfy the increasing demands of the doctors.

Against the background of the prevailing medical practice & market conditions, the image of pharma companies are of utmost importance says Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders, India is a challenging market where the promotion of the brands to the doctors & building the sustainable approach to the mindset of the doctors is a huge task & involves hard work & big bucks. All the five major players in the Nomination category such as 1.Zuventus Healthcare Ltd, Indoco Remedies Ltd,2.Aristo Pharmaceuticals Ltd,3.Ajanta Pharma Ltd,4.Blu-Cross Laboratories Ltd are enjoying the market dominance in their respective therapeutic segments & have employed innovative strategies to woo them, the final verdict lies with the doctors as nearly 35000 doctors will vote the coveted title, ‘India’s Most Respected Company by Medical Practitioners 2013”. While the first generation entrepreneur Prakash Guha is spearheading Zuventus Healthcare, veteran Suresh Kare is driving Indoco Remedies, Sharma Brothers are running the Aristo Brand & Isranis & Purushottam Agrawal are driving Blucross & Ajanta Pharma respectively.

The Indian pharmaceutical market (IPM) is currently valued at Rs 72,069 crore as against Rs 65,654 crore in 2012 & though Though the market value has seen an increase, the sector overall has experienced a slowdown with its growth going down to 9.8% from 16.6% in 2012. This slowdown can be attributed to the new drug pricing policy and the regulatory interventions over the last year, The industry is witnessing additional challenges like delays in clinical trial approvals, uncertainties over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing. The slowdown is also evident from the number of new product launches, which has gone down from approximately 1900 in year 2010 to 1700 in year 2012. The contribution of chronic therapies to the IPM has gone up from 27% in 2010 to 30% in 2013. Chronic therapies (cardio, gastro, CNS and anti-diabetic) have outperformed the market for the past four years and are growing at a rate of 14%, faster than the acute therapies (anti-infectives, respiratory, pain and gynaec) which grew at 9.6%. “The economic environment in India is tougher now than ever before. While pharma companies focus their attention on measures to combat the growth slowdown, they will need to work with the government and other stakeholders to discuss and resolve regulatory challenges. Resolving the impasse with clinical trials is critical both for patients and India’s ambition to innovate.”.According to the report, India is perceived as an attractive destination for clinical trials but has been marred with genuine concerns. Clinical trials are an inherent part of the drug development process and cannot be dispensed with. The continuing search for new therapies and cost-effective alternatives to existing therapies will be realised in practice only after comprehensive clinical trials.The clinical research industry in India needs to work closely with the government to create a regulatory mechanism that allows scientifically sound and ethically correct trials to be conducted so that the benefits of clinical trials can be brought to patients in India.The industry is also facing stricter regulations on manufacturing and quality practices in the domestic as well as he international markets. Indian companies will have to raise their compliance to US FDA regulations as they drive their major share of exports from the US market.The implementation of the National Pharmaceutical Pricing Policy 2012 by the Government of India has resulted in margins erosion from 20% and 10% to 16% and 8% for retailers and stockists, respectively. This decrease in the stockist margins led to a significant uncertainty among many stockists regarding the feasibility of staying in business due to lower profitability post the margin reduction.

The final result of the winner will be declared on the award presentation ceremony on Friday, 27th December 2013 in Mumbai, India.

Contacts :

6th Annual Pharmaceutical Leadership Summit 
Unit No. 53, 2nd Floor,
Aditya Indistrial Estate,
Devrukhkarwadi, Chincholi Bunder,
Malad (W), Mumbai – 400 064
Phone: + 91 22 4248 1240 / 4248 1234 / 4248 1235
Mr Anish Khan : ++ 91 9819499475
Ms Amrapali : ++ 91 9594030372 
Email : registrations@pharmaleaders2013.com
Email : pharmasummit2013@webevents.in 
Web : http://www.pharmaleaders2013.com

India Set to Crown the best Cosmetic Dermatologist at Pharmaleaders 2013 Summit & Awards, the rise of profession goes manifold says research

India Set to Crown the best Cosmetic Dermatologist at Pharmaleaders 2013 Summit & Awards, the rise of profession goes manifold says research

Dr.Chytra V Anand, Dr. Malavika Kohli, Dr. Apratim Goel, Dr. Chetana Kumar &  Dr. Shuba Dharmana are final nominees for the coveted title of India’s Most Respected Cosmetic Dermatologist 2013. Indian Derma Market set to triplicate in 2015.

Image

Wednesday,13th November 2013, Mumbai, Maharashtra : With the rise in the demand for the total transformation of the body & face, Indian Wellness Industry, the sector of skincare treatment & the increasing number of consultants in Cosmetic Dermatology is set to witness exponential growth as new india prepares to embrace latest innovations in cosmetic dermatology & no surprise for guessing, there are more number of consultants in the medical profession in cosmetic dermatology than it was a decade back. According to the latest data research by Pharmaleaders ( www.pharmaleaders.tv ), the Indian market has shown tremendous response in the skincare treatment with a whopping 62 % of the younger generation in the age group of 22 to 30 of the tier 1 & tier 2 cities are ready to spend extra from their pocket in order to change their look & style while more than 34 % of the population in the age group of 30 to 45 & in tier 1 & tier 2 cities are willing to shed their extra weight in consulting Dermatologists to lose weight by medication & treatment.

As India prepares to vote India’s Most Admired Cosmetic Dermatologist 2013 at the historic 6th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2013 ( www.pharmaleaders2013.com ) organized by Pharmaleaders, a division of Network 7 Media Group in association with various associations & Ministry of Commerce, at the commercial capital of Mumbai on 27th December at Hotel Hilton, Mumbai international Airport, Mumbai, India, the race for the top five finalists in the voting nomination category went viral as more than 20,000 votes were cast in four days via sms & email on a sample size of 1.2 Lakh voters consisting of business circles, Doctors, Hospitals & Research Institutions. In the race are country’s top five names such as 1. Dr.Chytra V Anand, – Founder, CEO & Chief Cosmetic Dermatologist, KOSMORDEMA, Dr. Malavika Kohli, CEO & Founder, Skin secrets, Dr. Apratim Goel, CEO & Founder, Goel’s Cutis Skin Studio, Dr. Chetana Kumar, Director, Laser Cosmetics, 5. Dr. Shuba Dharmana,CEO & Founder,Le’jeune Medspa.

Speaking on the sideline of the India’s Most Respected Cosmetic Dermatologist 2013 category where top five contestants are in the race, Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders said “ It is difficult to select the one from the five nominees as all the five finalists are winners in their own field in their respective regions & treatment process, but it will be interesting to see how these nominees have embraced technology & infrastructure in their treatment process. While most of the Nominees have spent their learning times abroad, india will continue to surprise as the market for the skincare treatment is huge & challenging with rapid increase in healthcare innovations”.

There exists a high potential for R&D in the derma market, especially since most of the agents take care of the signs and symptoms and not the underlying cause of the disorders, except for infective disorders. In the aesthetic or skin care market, there is a high potential to do research in the field of aging and hyper-pigmentation. And with the entry and success of premium priced skin care products in India coupled with increase in the number of interventions and aesthetic procedures conducted in the country, along with the fact that many dermatologists are now taking higher training in aesthetic dermatology, the dermatology market will grow at a rate more than 45 per cent year-on- year.

The future of dermatology market has huge potential as the total number of dermatologists have almost doubled in last one decade, and that clinical dermatology will remain the mainstay, whereas aesthetics/cosmetology segment will prosper even in the rural areas because of increased awareness and availability of knowledgeable/skilled doctors. “The key areas will be psoriasis, eczema, hair nutrition, facial upliftment, peels and fillers, hair transplant to name few, Many companies & even cosmetic dermatologists are jumping into the field of cosmetology and more research and advancement will be seen in painless dermal procedures.

Cosmetic dermatology is also expected to grow in tier I and II cities with increasing spending power and the high aspirational value. The Indian dermatology market is poised for growth. “At its current growth rate we expect the trend to continue, with growth at around 20 per cent over the next three to four years. The segment is still not highly crowded, as it has few players, but it has immense potential in the Indian market. Over the counter (OTC) products are also large segments in the market, and will propel growth. Due to importance of patents, Indian companies can also look at licensing some innovator products for the Indian market.” While the treatment of skin related disorders remains the primary segment for derma, the sector driving growth will be cosmetic dermatology since it is of high value. “Research for psoriasis and cosmetological applications of drugs will be key. The derma market depends a lot upon the type of products, while cosmetic dermatology can be considered as a luxury. However, for treatment related products, the market is directly dependent upon the number of patients who can afford the treatment. Basic treatments for skin related disorders are always in demand, however, since most medical spending in India is mainly out-of-pocket, the drug sales can be expected to be higher in metros and tier II cities than in all rural areas as well. With an increase in pollution, stress and poor nutrition, many skin disorders have become more common in India, and that will definitely drive the market. The importance of skin has increased in recent years. With successful surgery, treatment of surgical scars and other wounds has become an equally important area. Patients today are willing to pay for-state-of-the-art treatments.

The final result of the winner will be announced on the Friday evening in a glittering award ceremony at hotel Hilton, Mumbai on 27th December.